<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02550197</url>
  </required_header>
  <id_info>
    <org_study_id>GQM07</org_study_id>
    <secondary_id>U1111-1143-9015</secondary_id>
    <nct_id>NCT02550197</nct_id>
  </id_info>
  <brief_title>Immunogenicity and Safety of a Quadrivalent Influenza Vaccine Given by Intramuscular Route in Subjects Aged 18 to 60 Years</brief_title>
  <official_title>Immunogenicity and Safety of a Quadrivalent Influenza Vaccine Administered Via the Intramuscular Route in Subjects Aged 18 to 60 Years in the Republic of Korea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi Pasteur, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the trial is to evaluate immunogenicity and safety of the quadrivalent influenza
      vaccine (QIV) and the trivalent influenza vaccine (TIV) (split-virion inactivated) Northern
      Hemisphere (NH) 2015 2016 seasonal formulations, in subjects aged 18 to 60 years in the
      Republic of Korea for the registration of the QIV by the Ministry of Food and Drug Safety.

      Objectives:

        -  To evaluate the immunogenicity of QIV and TIV (split-virion, inactivated) NH 2015-2016
           seasonal formulations. The compliance, in terms of immunogenicity, of the QIV NH
           2015-2016 formulation, with the requirements of the Committee for Medicinal Products for
           Human Use (CHMP) Note for Guidance (NfG) CPMP/BWP/214/96 will be assessed.

        -  To evaluate the safety profile of QIV and TIV (split-virion, inactivated) NH 2015-2016
           seasonal formulations
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All subjects will receive one dose of either QIV or TIV on Day 0. They will be monitored for
      safety and immunogenicity for up to Day 21 post-vaccination.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Geometric Mean Titers of Influenza Antibodies Before and After Vaccination With a Quadrivalent Influenza Vaccine Administered Via the Intramuscular Route</measure>
    <time_frame>Day 0 (pre-vaccination) and Day 21 post-vaccination</time_frame>
    <description>Immunogenicity was evaluated using the hemagglutination inhibition (HAI) technique.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Achieving Seroprotection Against Influenza Antigens Before and After Vaccination With a Quadrivalent Influenza Vaccine Administered Via the Intramuscular Route</measure>
    <time_frame>Day 0 (pre-vaccination) and Day 21 post-vaccination</time_frame>
    <description>Immunogenicity was evaluated using the hemagglutination inhibition (HAI) technique. Seroprotection was defined as titers ≥ 40 (1/dil) on Day 0 and Day 21.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Influenza Antibodies Titers &lt; 10 (1/Dil) Before and After Vaccination With a Quadrivalent Influenza Vaccine Administered Via the Intramuscular Route</measure>
    <time_frame>Day 0 (pre-vaccination) and Day 21 post-vaccination</time_frame>
    <description>Immunogenicity was evaluated using the hemagglutination inhibition (HAI) technique.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Achieving Seroconversion or Significant Increase Against Influenza Antigens After Vaccination With a Quadrivalent Influenza Vaccine Administered Via the Intramuscular Route</measure>
    <time_frame>Day 21 post-vaccination</time_frame>
    <description>Immunogenicity was evaluated using the hemagglutination inhibition (HAI) technique. Seroconversion was defined as titers &lt; 10 (1/dil) on Day 0 and post-injection titer ≥ 40 (1/dil) on Day 21, and Significant increase was defined as titers ≥ 10 (1/dil) on Day 0 and ≥ 4-fold increase of post-injection titer on Day 21.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Titer Ratios of Influenza Virus Antibodies After Vaccination With a Quadrivalent Influenza Vaccine Administered Via the Intramuscular Route</measure>
    <time_frame>Day 0 (pre-vaccination) and Day 21 post-vaccination</time_frame>
    <description>Immunogenicity was evaluated using the hemagglutination inhibition (HAI) technique.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Reporting Solicited Reactions Listed in The Former Committee for Medicinal Products for Human Use Note for Guidance Within 3 Days After Vaccination With a Quadrivalent Influenza Vaccine Administered Via the Intramuscular Route</measure>
    <time_frame>Day 0 up Day 3 post-vaccination</time_frame>
    <description>The solicited reactions evaluated were Injection-site Induration (≥50 mm for at least 4 consecutive days), Injection-site Ecchymosis (injection site bruising), Pyrexia (recorded temperature &gt;38.0˚C for at least 1 day), Malaise, and Shivering (rigors).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Reporting Solicited Injection-Site or Systemic Reaction After Vaccination With a Quadrivalent Influenza Vaccine Administered Via the Intramuscular Route</measure>
    <time_frame>Day 0 up Day 7 post-vaccination</time_frame>
    <description>Solicited Injection-site reactions: Pain, Erythema, Swelling, Induration, and Ecchymosis. Solicited Systemic reactions: Fever, Headache, Malaise, Myalgia, and Shivering. Grade 3: Pain, Significant; prevents daily activity; Erythema, Swelling, Induration, and Ecchymosis, &gt;100 mm. Grade 3 Solicited Systemic reactions: Fever, ≥ 39.0˚C; Headache, Malaise, Myalgia, and Shivering, Significant; prevents daily activity.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">300</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>QIV Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive one dose of the Quadrivalent influenza vaccine (QIV) (split virion, inactivated) Northern Hemisphere (NH) 2015-2016 formulation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TIV Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will receive one dose of the Trivalent influenza vaccine (TIV) (split virion, inactivated) NH 2015-2016 formulation</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Quadrivalent influenza vaccine (QIV) (split virion, inactivated) Northern Hemisphere (NH) 2015-2016</intervention_name>
    <description>0.5 mL, Intramuscular</description>
    <arm_group_label>QIV Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Trivalent influenza vaccine (TIV) (split virion, inactivated) NH 2015-2016 formulation</intervention_name>
    <description>0.5 mL, Intramuscular</description>
    <arm_group_label>TIV Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged 18 to 60 years on the day of inclusion

          -  Subjects aged 18 years: Assent form has been signed and dated by the subject or by an
             independent witness, and informed consent form has been signed and dated by at least
             one parent or another legally acceptable representative or by an independent witness
             Subjects aged 19 to 60 years: Informed consent form has been signed and dated by the
             subject or by an independent witness

          -  Subject and parent/legally acceptable representative (if applicable) are able to
             attend all scheduled visits and to comply with all trial procedures

        Exclusion Criteria:

          -  Subject is pregnant, or lactating, or of childbearing potential (to be considered of
             non-childbearing potential, a female must be pre-menarche or post-menopausal for at
             least 1 year, surgically sterile, or using an effective method of contraception or
             abstinence from at least 4 weeks prior to vaccination and until at least 3 weeks after
             vaccination)

          -  Participation at the time of study enrollment (or in the 4 weeks preceding the trial
             vaccination) or planned participation during the present trial period in another
             clinical trial investigating a vaccine, drug, medical device, or medical procedure

          -  Receipt of any vaccine in the 4 weeks preceding the trial vaccination or planned
             receipt of any vaccine until the second visit, 3 weeks following the trial vaccination

          -  Vaccination against influenza if administered in the context of a clinical trial or a
             flu vaccination campaign or self-reported history of influenza infection
             (influenza-like illness) in the previous 6 months

          -  Receipt of immune globulins, blood or blood-derived products in the past 3 months

          -  Known or suspected congenital or acquired immunodeficiency; or receipt of
             immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy,
             within the preceding 6 months; or long-term systemic corticosteroid therapy
             (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months)

          -  Known history of seropositivity for Human Immunodeficiency Virus (HIV) or Hepatitis C

          -  Known systemic hypersensitivity to eggs, chicken proteins, neomycin, formaldehyde and
             octoxynol-9, or to any of the vaccine components, or history of a life-threatening
             reaction to the vaccines used in the study or to a vaccine containing any of the same
             substances

          -  Known or suspected thrombocytopenia, contraindicating intramuscular vaccination, based
             on Investigator's judgment

          -  Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion,
             contraindicating intramuscular vaccination, based on Investigator's judgment

          -  Deprived of freedom by an administrative or court order, or in an emergency setting,
             or hospitalized involuntarily

          -  Current alcohol abuse or drug addiction

          -  Chronic illness that, in the opinion of the investigator, is at a stage where it might
             interfere with trial conduct or completion

          -  Moderate or severe acute illness/infection (according to investigator judgment) on the
             day of vaccination or febrile illness (temperature ≥ 38.0°C). A prospective subject
             should not be included in the study until the condition has resolved or the febrile
             event has subsided

          -  Identified as an Investigator or employee of the Investigator or study center with
             direct involvement in the proposed study, or identified as an immediate family member
             (i.e., parent, spouse, natural or adopted child) of the Investigator or employee with
             direct involvement in the proposed study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi Pasteur SA</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Ansan-si</city>
        <zip>425-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Incheon</city>
        <zip>400-712</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>150-950</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>152-840</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <link>
    <url>http://www.sanofipasteur.com</url>
  </link>
  <link>
    <url>http://www.sanofi.com</url>
  </link>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 11, 2015</study_first_submitted>
  <study_first_submitted_qc>September 11, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2015</study_first_posted>
  <results_first_submitted>September 16, 2016</results_first_submitted>
  <results_first_submitted_qc>September 16, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 4, 2016</results_first_posted>
  <last_update_submitted>September 16, 2016</last_update_submitted>
  <last_update_submitted_qc>September 16, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 4, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Influenza</keyword>
  <keyword>Quadrivalent influenza vaccine</keyword>
  <keyword>Trivalent influenza vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant data (IPD) and supporting clinical documents are available for request at www.clinicalstudydatarequest.com. While making information available we continue to protect the privacy of the participants in our clinical trials and to remove commercially confidential information (CCI). Details on Data Sharing criteria and process for requesting access can be found at this web address: Clinicalstudydatarequest.com/Sanofi.</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study participants were enrolled from 11 September 2015 to 03 November 2015 at 5 clinic sites in the Republic of Korea.</recruitment_details>
      <pre_assignment_details>A total of 300 participants who met all inclusion and no exclusion criteria were enrolled and vaccinated.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Quadrivalent Influenza Vaccine Group</title>
          <description>Participants received one dose of the quadrivalent influenza vaccine (QIV) (split virion, inactivated) Northern Hemisphere (NH) 2015-2016 formulation by the intramuscular route.</description>
        </group>
        <group group_id="P2">
          <title>Trivalent Influenza Vaccine Group</title>
          <description>Participants received one dose of the trivalent influenza vaccine (TIV) (split virion, inactivated) NH 2015-2016 formulation by the Intramuscular route.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="200"/>
                <participants group_id="P2" count="100"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="200"/>
                <participants group_id="P2" count="100"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Quadrivalent Influenza Vaccine Group</title>
          <description>Participants received one dose of the quadrivalent influenza vaccine (QIV) (split virion, inactivated) Northern Hemisphere (NH) 2015-2016 formulation by the intramuscular route.</description>
        </group>
        <group group_id="B2">
          <title>Trivalent Influenza Vaccine Group</title>
          <description>Participants received one dose of the trivalent influenza vaccine (TIV) (split virion, inactivated) NH 2015-2016 formulation by the Intramuscular route.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="200"/>
            <count group_id="B2" value="100"/>
            <count group_id="B3" value="300"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="200"/>
                    <measurement group_id="B2" value="100"/>
                    <measurement group_id="B3" value="300"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Age Continuous</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.9" spread="9.1"/>
                    <measurement group_id="B2" value="35.6" spread="9.5"/>
                    <measurement group_id="B3" value="35.8" spread="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="150"/>
                    <measurement group_id="B2" value="71"/>
                    <measurement group_id="B3" value="221"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Korea, Republic of</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="200"/>
                    <measurement group_id="B2" value="100"/>
                    <measurement group_id="B3" value="300"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titers of Influenza Antibodies Before and After Vaccination With a Quadrivalent Influenza Vaccine Administered Via the Intramuscular Route</title>
        <description>Immunogenicity was evaluated using the hemagglutination inhibition (HAI) technique.</description>
        <time_frame>Day 0 (pre-vaccination) and Day 21 post-vaccination</time_frame>
        <population>Geometric mean titers of influenza antibodies were assessed in the Immunogenicity Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Quadrivalent Influenza Vaccine Group</title>
            <description>Participants received one dose of the quadrivalent influenza vaccine (QIV) (split virion, inactivated) Northern Hemisphere (NH) 2015-2016 formulation by the intramuscular route.</description>
          </group>
          <group group_id="O2">
            <title>Trivalent Influenza Vaccine Group</title>
            <description>Participants received one dose of the trivalent influenza vaccine (TIV) (split virion, inactivated) NH 2015-2016 formulation by the Intramuscular route.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers of Influenza Antibodies Before and After Vaccination With a Quadrivalent Influenza Vaccine Administered Via the Intramuscular Route</title>
          <description>Immunogenicity was evaluated using the hemagglutination inhibition (HAI) technique.</description>
          <population>Geometric mean titers of influenza antibodies were assessed in the Immunogenicity Analysis Set.</population>
          <units>Titers (1/dilution)</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="199"/>
                <count group_id="O2" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1; Day 0 (N=199, 99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="142" lower_limit="116" upper_limit="174"/>
                    <measurement group_id="O2" value="116" lower_limit="86.1" upper_limit="155"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1; Day 21 (N=199, 99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="583" lower_limit="516" upper_limit="658"/>
                    <measurement group_id="O2" value="651" lower_limit="550" upper_limit="771"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2; Day 0 (N=199, 99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.6" lower_limit="34.1" upper_limit="50.9"/>
                    <measurement group_id="O2" value="35.8" lower_limit="27.2" upper_limit="47.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2; Day 21 (N=199, 99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="483" lower_limit="406" upper_limit="574"/>
                    <measurement group_id="O2" value="691" lower_limit="543" upper_limit="881"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Phuket; Day 0 (N=199, 99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="256" lower_limit="212" upper_limit="309"/>
                    <measurement group_id="O2" value="219" lower_limit="166" upper_limit="290"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Phuket; Day 21 (N=199, 99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1068" lower_limit="950" upper_limit="1200"/>
                    <measurement group_id="O2" value="1105" lower_limit="933" upper_limit="1308"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Bris; Day 0 (N=199, 100)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="186" lower_limit="156" upper_limit="220"/>
                    <measurement group_id="O2" value="139" lower_limit="107" upper_limit="180"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Bris; Day 21 (N=199, 100)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="737" lower_limit="651" upper_limit="835"/>
                    <measurement group_id="O2" value="290" lower_limit="231" upper_limit="364"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Achieving Seroprotection Against Influenza Antigens Before and After Vaccination With a Quadrivalent Influenza Vaccine Administered Via the Intramuscular Route</title>
        <description>Immunogenicity was evaluated using the hemagglutination inhibition (HAI) technique. Seroprotection was defined as titers ≥ 40 (1/dil) on Day 0 and Day 21.</description>
        <time_frame>Day 0 (pre-vaccination) and Day 21 post-vaccination</time_frame>
        <population>Seroprotection was assessed in the Immunogenicity Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Quadrivalent Influenza Vaccine Group</title>
            <description>Participants received one dose of the quadrivalent influenza vaccine (QIV) (split virion, inactivated) Northern Hemisphere (NH) 2015-2016 formulation by the intramuscular route.</description>
          </group>
          <group group_id="O2">
            <title>Trivalent Influenza Vaccine Group</title>
            <description>Participants received one dose of the trivalent influenza vaccine (TIV) (split virion, inactivated) NH 2015-2016 formulation by the Intramuscular route.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Seroprotection Against Influenza Antigens Before and After Vaccination With a Quadrivalent Influenza Vaccine Administered Via the Intramuscular Route</title>
          <description>Immunogenicity was evaluated using the hemagglutination inhibition (HAI) technique. Seroprotection was defined as titers ≥ 40 (1/dil) on Day 0 and Day 21.</description>
          <population>Seroprotection was assessed in the Immunogenicity Analysis Set.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="199"/>
                <count group_id="O2" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1; Day 0 (N=199, 99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.4"/>
                    <measurement group_id="O2" value="78.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1; Day 21 (N=199, 99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.5"/>
                    <measurement group_id="O2" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2; Day 0 (N=199, 99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.3"/>
                    <measurement group_id="O2" value="55.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2; Day 21 (N=199, 99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.0"/>
                    <measurement group_id="O2" value="99.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Phuket; Day 0 (N=199, 99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.5"/>
                    <measurement group_id="O2" value="87.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Phuket; Day 21 (N=199, 99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Bris; Day 0 (N=199, 100)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.4"/>
                    <measurement group_id="O2" value="85.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Bris; Day 21 (N=199, 100)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="97.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Influenza Antibodies Titers &lt; 10 (1/Dil) Before and After Vaccination With a Quadrivalent Influenza Vaccine Administered Via the Intramuscular Route</title>
        <description>Immunogenicity was evaluated using the hemagglutination inhibition (HAI) technique.</description>
        <time_frame>Day 0 (pre-vaccination) and Day 21 post-vaccination</time_frame>
        <population>Immunogenicity was assessed in the Immunogenicity Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Quadrivalent Influenza Vaccine Group</title>
            <description>Participants received one dose of the quadrivalent influenza vaccine (QIV) (split virion, inactivated) Northern Hemisphere (NH) 2015-2016 formulation by the intramuscular route.</description>
          </group>
          <group group_id="O2">
            <title>Trivalent Influenza Vaccine Group</title>
            <description>Participants received one dose of the trivalent influenza vaccine (TIV) (split virion, inactivated) NH 2015-2016 formulation by the Intramuscular route.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Influenza Antibodies Titers &lt; 10 (1/Dil) Before and After Vaccination With a Quadrivalent Influenza Vaccine Administered Via the Intramuscular Route</title>
          <description>Immunogenicity was evaluated using the hemagglutination inhibition (HAI) technique.</description>
          <population>Immunogenicity was assessed in the Immunogenicity Analysis Set.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="199"/>
                <count group_id="O2" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1; Day 0 (N=199, 99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.5"/>
                    <measurement group_id="O2" value="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1; Day 21 (N=199, 99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2; Day 0 (N=199, 99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.1"/>
                    <measurement group_id="O2" value="20.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2; Day 21 (N=199, 99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Phuket; Day 0 (N=199, 99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5"/>
                    <measurement group_id="O2" value="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Phuket; Day 21 (N=199, 99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Bris; Day 0 (N=199, 100)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5"/>
                    <measurement group_id="O2" value="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Bris; Day 21 (N=199, 100)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Achieving Seroconversion or Significant Increase Against Influenza Antigens After Vaccination With a Quadrivalent Influenza Vaccine Administered Via the Intramuscular Route</title>
        <description>Immunogenicity was evaluated using the hemagglutination inhibition (HAI) technique. Seroconversion was defined as titers &lt; 10 (1/dil) on Day 0 and post-injection titer ≥ 40 (1/dil) on Day 21, and Significant increase was defined as titers ≥ 10 (1/dil) on Day 0 and ≥ 4-fold increase of post-injection titer on Day 21.</description>
        <time_frame>Day 21 post-vaccination</time_frame>
        <population>Immunogenicity was assessed in the Immunogenicity Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Quadrivalent Influenza Vaccine Group</title>
            <description>Participants received one dose of the quadrivalent influenza vaccine (QIV) (split virion, inactivated) Northern Hemisphere (NH) 2015-2016 formulation by the intramuscular route.</description>
          </group>
          <group group_id="O2">
            <title>Trivalent Influenza Vaccine Group</title>
            <description>Participants received one dose of the trivalent influenza vaccine (TIV) (split virion, inactivated) NH 2015-2016 formulation by the Intramuscular route.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Seroconversion or Significant Increase Against Influenza Antigens After Vaccination With a Quadrivalent Influenza Vaccine Administered Via the Intramuscular Route</title>
          <description>Immunogenicity was evaluated using the hemagglutination inhibition (HAI) technique. Seroconversion was defined as titers &lt; 10 (1/dil) on Day 0 and post-injection titer ≥ 40 (1/dil) on Day 21, and Significant increase was defined as titers ≥ 10 (1/dil) on Day 0 and ≥ 4-fold increase of post-injection titer on Day 21.</description>
          <population>Immunogenicity was assessed in the Immunogenicity Analysis Set.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="199"/>
                <count group_id="O2" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1 (N=199, 99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.7"/>
                    <measurement group_id="O2" value="46.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 (N=199, 99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.4"/>
                    <measurement group_id="O2" value="84.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Phuket (N=199, 99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.7"/>
                    <measurement group_id="O2" value="53.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Bris (N=199, 100)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.2"/>
                    <measurement group_id="O2" value="23.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titer Ratios of Influenza Virus Antibodies After Vaccination With a Quadrivalent Influenza Vaccine Administered Via the Intramuscular Route</title>
        <description>Immunogenicity was evaluated using the hemagglutination inhibition (HAI) technique.</description>
        <time_frame>Day 0 (pre-vaccination) and Day 21 post-vaccination</time_frame>
        <population>Geometric mean titer ratios of influenza antibodies were assessed in the Immunogenicity Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Quadrivalent Influenza Vaccine Group</title>
            <description>Participants received one dose of the quadrivalent influenza vaccine (QIV) (split virion, inactivated) Northern Hemisphere (NH) 2015-2016 formulation by the intramuscular route.</description>
          </group>
          <group group_id="O2">
            <title>Trivalent Influenza Vaccine Group</title>
            <description>Participants received one dose of the trivalent influenza vaccine (TIV) (split virion, inactivated) NH 2015-2016 formulation by the Intramuscular route.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titer Ratios of Influenza Virus Antibodies After Vaccination With a Quadrivalent Influenza Vaccine Administered Via the Intramuscular Route</title>
          <description>Immunogenicity was evaluated using the hemagglutination inhibition (HAI) technique.</description>
          <population>Geometric mean titer ratios of influenza antibodies were assessed in the Immunogenicity Analysis Set.</population>
          <units>Titer ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="199"/>
                <count group_id="O2" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1 (N=199, 99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.10" lower_limit="3.30" upper_limit="5.09"/>
                    <measurement group_id="O2" value="5.64" lower_limit="4.09" upper_limit="7.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 (N=199, 99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.6" lower_limit="9.16" upper_limit="14.7"/>
                    <measurement group_id="O2" value="19.3" lower_limit="13.9" upper_limit="26.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Phuket (N=199, 99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.17" lower_limit="3.49" upper_limit="4.98"/>
                    <measurement group_id="O2" value="5.04" lower_limit="3.81" upper_limit="6.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Bris (N=199, 100)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.97" lower_limit="3.30" upper_limit="4.78"/>
                    <measurement group_id="O2" value="2.08" lower_limit="1.75" upper_limit="2.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Reporting Solicited Reactions Listed in The Former Committee for Medicinal Products for Human Use Note for Guidance Within 3 Days After Vaccination With a Quadrivalent Influenza Vaccine Administered Via the Intramuscular Route</title>
        <description>The solicited reactions evaluated were Injection-site Induration (≥50 mm for at least 4 consecutive days), Injection-site Ecchymosis (injection site bruising), Pyrexia (recorded temperature &gt;38.0˚C for at least 1 day), Malaise, and Shivering (rigors).</description>
        <time_frame>Day 0 up Day 3 post-vaccination</time_frame>
        <population>Solicited reactions were analyzed in the Safety Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Quadrivalent Influenza Vaccine Group</title>
            <description>Participants received one dose of the quadrivalent influenza vaccine (QIV) (split virion, inactivated) Northern Hemisphere (NH) 2015-2016 formulation by the intramuscular route.</description>
          </group>
          <group group_id="O2">
            <title>Trivalent Influenza Vaccine Group</title>
            <description>Participants received one dose of the trivalent influenza vaccine (TIV) (split virion, inactivated) NH 2015-2016 formulation by the Intramuscular route.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Solicited Reactions Listed in The Former Committee for Medicinal Products for Human Use Note for Guidance Within 3 Days After Vaccination With a Quadrivalent Influenza Vaccine Administered Via the Intramuscular Route</title>
          <description>The solicited reactions evaluated were Injection-site Induration (≥50 mm for at least 4 consecutive days), Injection-site Ecchymosis (injection site bruising), Pyrexia (recorded temperature &gt;38.0˚C for at least 1 day), Malaise, and Shivering (rigors).</description>
          <population>Solicited reactions were analyzed in the Safety Analysis Set.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="200"/>
                <count group_id="O2" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Reaction listed in the EMA note for guidance</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.5"/>
                    <measurement group_id="O2" value="40.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site Induration (≥50 mm for 4 days)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site Ecchymosis (Inj. site Bruising)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.0"/>
                    <measurement group_id="O2" value="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pyrexia (temperature &gt;38.0˚C for at least 1 day)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.0"/>
                    <measurement group_id="O2" value="40.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Shivering (Rigors)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.5"/>
                    <measurement group_id="O2" value="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Reporting Solicited Injection-Site or Systemic Reaction After Vaccination With a Quadrivalent Influenza Vaccine Administered Via the Intramuscular Route</title>
        <description>Solicited Injection-site reactions: Pain, Erythema, Swelling, Induration, and Ecchymosis. Solicited Systemic reactions: Fever, Headache, Malaise, Myalgia, and Shivering. Grade 3: Pain, Significant; prevents daily activity; Erythema, Swelling, Induration, and Ecchymosis, &gt;100 mm. Grade 3 Solicited Systemic reactions: Fever, ≥ 39.0˚C; Headache, Malaise, Myalgia, and Shivering, Significant; prevents daily activity.</description>
        <time_frame>Day 0 up Day 7 post-vaccination</time_frame>
        <population>Solicited injection-site and systemic reactions were analyzed in the Safety Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Quadrivalent Influenza Vaccine Group</title>
            <description>Participants received one dose of the quadrivalent influenza vaccine (QIV) (split virion, inactivated) Northern Hemisphere (NH) 2015-2016 formulation by the intramuscular route.</description>
          </group>
          <group group_id="O2">
            <title>Trivalent Influenza Vaccine Group</title>
            <description>Participants received one dose of the trivalent influenza vaccine (TIV) (split virion, inactivated) NH 2015-2016 formulation by the Intramuscular route.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Solicited Injection-Site or Systemic Reaction After Vaccination With a Quadrivalent Influenza Vaccine Administered Via the Intramuscular Route</title>
          <description>Solicited Injection-site reactions: Pain, Erythema, Swelling, Induration, and Ecchymosis. Solicited Systemic reactions: Fever, Headache, Malaise, Myalgia, and Shivering. Grade 3: Pain, Significant; prevents daily activity; Erythema, Swelling, Induration, and Ecchymosis, &gt;100 mm. Grade 3 Solicited Systemic reactions: Fever, ≥ 39.0˚C; Headache, Malaise, Myalgia, and Shivering, Significant; prevents daily activity.</description>
          <population>Solicited injection-site and systemic reactions were analyzed in the Safety Analysis Set.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="200"/>
                <count group_id="O2" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Injection-site Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.5"/>
                    <measurement group_id="O2" value="64.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Injection-site Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Injection-site Erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5"/>
                    <measurement group_id="O2" value="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Injection-site Erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Injection-site Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Injection-site Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Injection-site Induration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0"/>
                    <measurement group_id="O2" value="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Injection-site Induration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Injection-site Ecchymosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Injection-site Ecchymosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.5"/>
                    <measurement group_id="O2" value="20.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5"/>
                    <measurement group_id="O2" value="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Malaise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.5"/>
                    <measurement group_id="O2" value="42.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Malaise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5"/>
                    <measurement group_id="O2" value="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.0"/>
                    <measurement group_id="O2" value="49.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Shivering</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.5"/>
                    <measurement group_id="O2" value="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Shivering</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were collected from Day 0 up to Day 21 post-vaccination.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Quadrivalent Influenza Vaccine Group</title>
          <description>Participants received one dose of the quadrivalent influenza vaccine (QIV) (split virion, inactivated) Northern Hemisphere (NH) 2015-2016 formulation by the intramuscular route.</description>
        </group>
        <group group_id="E2">
          <title>Trivalent Influenza Vaccine Group</title>
          <description>Participants received one dose of the trivalent influenza vaccine (TIV) (split virion, inactivated) NH 2015-2016 formulation by the Intramuscular route.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5.00</frequency_threshold>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="141" subjects_at_risk="200"/>
                <counts group_id="E2" subjects_affected="64" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site Pain</sub_title>
                <counts group_id="E1" events="141" subjects_affected="141" subjects_at_risk="200"/>
                <counts group_id="E2" events="64" subjects_affected="64" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="67" subjects_affected="67" subjects_at_risk="200"/>
                <counts group_id="E2" events="42" subjects_affected="42" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Shivering</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="200"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="102" subjects_affected="102" subjects_at_risk="200"/>
                <counts group_id="E2" events="49" subjects_affected="49" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="33" subjects_affected="33" subjects_at_risk="200"/>
                <counts group_id="E2" events="20" subjects_affected="20" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Director</name_or_title>
      <organization>Sanofi Pasteur Inc.</organization>
      <email>RegistryContactUs@sanofipasteur.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

